New CMOs at ImmPACT, Smart Immune
Plus CEO named at Prolifagen, and updates from Endpoint, Veracyte, Vyriad and more
CAR T cell therapies company ImmPACT Bio USA Inc. named Jonathan Benjamin as CMO. Benjamin was previously SVP of clinical research at Atreca Inc. (NASDAQ:BCEL) and medical director at Amgen Inc. (NASDAQ:AMGN), where he led design and execution of clinical trials for bispecific T cell engagers.
Smart Immune S.A.S. hired Frederic Lehmann as CMO and Pierre Heimendinger as CTO. Lehmann, a 12-year veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), was head of clinical development and medical affairs and VP of Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD). He succeeds Marina Cavazzana, who will become strategic clinical development adviser. Heimendinger was VP of pharmaceutical operations at Sangamo Therapeutics Inc. (NASDAQ:SGMO) and VP of process development at TxCell S.A. Smart Immune is developing ProTcell, a thymus empowered T cell therapy platform...